Literature DB >> 15142871

Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size.

Nick A Maskell1, Y C Gary Lee, Fergus V Gleeson, Emma L Hedley, Gerry Pengelly, Robert J O Davies.   

Abstract

We report two trials describing whether talc pleurodesis with a mean particle size of less than 15 microm ("mixed" talc) produces more lung and systemic inflammation than tetracycline or "graded" talc (most particles < 10 microm were removed). First, 20 patients with malignant effusions received tetracycline or mixed talc. Changes in lung and systemic inflammation from lung clearance scans, oxygen saturations, and C-reactive protein from baseline to 48 hours after pleurodesis were recorded. Lung inflammation (change in isotope clearance, talc -9.26, SD 14.3 vs. tetracycline 4.10, SD 13.8 minutes; difference = -13.4; 95% confidence interval [CI], -26.6 to -0.2; p = 0.05) and systemic inflammation (change in C-reactive protein, talc 198 SD 79.2 vs. tetracycline 74 SD 79.4 microg/L; difference = 124; 95% CI, 50 to 199; p = 0.004) were greater after talc. Second, 48 patients received mixed or graded talc, and gas exchange was assessed from changes in the alveolar-arterial oxygen gradient. Mixed talc worsened gas exchange (oxygen gradient change, mixed 2.17 SD 1.74 kPa, 16.3 13.1 mm Hg vs. graded 0.72 SD 2.46 kPa 5.4 18.5 mm Hg, difference = 1.45; 95% CI, 0.2 to 2.7; p = 0.03) and induced more systemic inflammation than graded talc. We conclude that the routine use of graded talc for pleurodesis would reduce the morbidity of this procedure.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15142871     DOI: 10.1164/rccm.200311-1579OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  38 in total

1.  BTS statement on malignant mesothelioma in the UK, 2007.

Authors: 
Journal:  Thorax       Date:  2007-11       Impact factor: 9.139

2.  Experimental validation of talc pleurodesis for carcinomatous pleuritis in an animal model.

Authors:  Yasunori Iwasaki; Shinzo Takamori; Masahiro Mitsuoka; Masaki Kashihara; Tatsuya Nishi; Daigo Murakami; Ryoichi Matsumoto; Hiroharu Mifune; Yuji Tajiri; Yoshito Akagi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-05-12

3.  Optimal management of malignant pleural effusions (results of CALGB 30102).

Authors:  Todd L Demmy; Lin Gu; Jack E Burkhalter; Eric M Toloza; Thomas A D'Amico; Susan Sutherland; Xiaofei Wang; Laura Archer; Linda J Veit; Leslie Kohman
Journal:  J Natl Compr Canc Netw       Date:  2012-08       Impact factor: 11.908

4.  Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion.

Authors:  Georgios T Stathopoulos; Taylor P Sherrill; Sophia P Karabela; Kasia Goleniewska; Ioannis Kalomenidis; Charis Roussos; Barbara Fingleton; Fiona E Yull; R Stokes Peebles; Timothy S Blackwell
Journal:  Am J Respir Crit Care Med       Date:  2010-07-01       Impact factor: 21.405

5.  Mesothelioid reaction following talc pleurodesis: a case report.

Authors:  Tatyana Faynberg; Neha Patel; Amrit P Nayar; Alan J Shienbaum
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-03-07

6.  Therapeutic effects of recombinant human endostatin adenovirus in a mouse model of malignant pleural effusion.

Authors:  Fang Fang; Ping Chen; Xin Wu; Li Yang; Xun Yang; Zhen-Xiang Xi; Bin-Wen Zhou; Xi-Kun Zhou; Zhi-Yong Qian; Bo Xiao; Yu-Quan Wei
Journal:  J Cancer Res Clin Oncol       Date:  2009-02-15       Impact factor: 4.553

7.  Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.

Authors:  Ioannis Psallidas; Sophia P Karabela; Charalampos Moschos; Taylor P Sherrill; Androniki Kollintza; Sophia Magkouta; Panagiota Theodoropoulou; Charis Roussos; Timothy S Blackwell; Ioannis Kalomenidis; Georgios T Stathopoulos
Journal:  Mol Cancer       Date:  2010-03-10       Impact factor: 27.401

Review 8.  Management of malignant pleural effusion.

Authors:  Jack A Kastelik
Journal:  Lung       Date:  2013-01-13       Impact factor: 2.584

9.  Recruitment and phenotypic characteristics of interleukin 9-producing CD4+ T cells in malignant pleural effusion.

Authors:  Xiao-Ning Bu; Qiong Zhou; Jian-Chu Zhang; Zhi-Jian Ye; Zhao-Hui Tong; Huan-Zhong Shi
Journal:  Lung       Date:  2013-05-23       Impact factor: 2.584

10.  Update on pleural diseases--2007.

Authors:  Ayman Bishay; Suhail Raoof; Adebayo Esan; Arthur Sung; Siraj Wali; Leonard Y Lee; Liziamma George; Anthony Saleh; Michael Baumann
Journal:  Ann Thorac Med       Date:  2007-07       Impact factor: 2.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.